Innovate Biopharmaceuticals Announces Presentation of Three Posters Focusing on the Molecular Biology and Pharmacology of Lar...
May 20 2019 - 9:45AM
Innovate Biopharmaceuticals, Inc. (Nasdaq: INNT), a clinical stage
biotechnology company focused on developing novel therapeutics for
autoimmune and inflammatory diseases, announced today that
larazotide acetate, a new class of medicine based on gut-restricted
peptides which re-normalize the intestinal epithelial barrier and
gut-liver axis, announced that three posters were presented on May
19 and 20, 2019 during the 2019 Digestive Disease Week (DDW)
conference in San Diego, CA (Abstract Search).
Title: Larazotide acetate prevents and rescues
from ethanol-induced permeability changes in an in vitro model
systemDate/Time: Saturday, May 18, 2019, 12:00pm – 2:00pm
PTPoster Session Title: Alcoholic Liver Diseases – Clinical &
Experimental Session Number: 6130Presentation Number: 1517
Title: Larazotide protects the intestinal tight
junction barrier during anoxia/reoxygenation injury via inhibition
of myosin light chain kinaseDate/Time: Sunday, May
19, 2019, 12:00pm – 2:00pm PTPoster Session Title: Epithelial
Junctions and Barrier FunctionSession Number: 7020Presentation
Number: 1019
Title: Establishment and characterization of a
leaky porcine jejunal cell line grown as a 2-dimensional monolayer
using crypt culture media and their response to the tight junction
agent larazotide acetate Date/Time: Sunday, May 19,
2019, 12:00pm – 2:00pm PTPoster Session Title: Cell Biology,
Biochem and Integrative PhysiologySession Number: 7015Presentation
Number: 1017
Analyst Meeting will be held at 4:30pm ET today, May 20, 2019 to
discuss NASH data and provide clinical updates. To access the
webcast, please visit the tab in the Events and Presentations
section of Innovate’s investor relations website.
About Alcoholic Liver Diseases (ALD) and Alcoholic
Steatohepatitis (ASH)Alcoholic liver disease (ALD)
comprises a spectrum of conditions arising from excessive alcohol
intake, from reversible fatty liver to acute alcoholic hepatitis,
chronic fibrosis and cirrhosis and hepatocellular cancer (HCC).
ALD, including progression from alcoholic fatty liver to alcoholic
steatohepatitis (ASH) is characterized by hepatic inflammation
which could lead to a chronic form leading to cirrhosis and, in
some cases, hepatocellular carcinoma. In addition, severe ASH (with
or without cirrhosis) can lead to alcoholic hepatitis, which is an
acute clinical presentation of ALD that is associated with liver
failure and high mortality. The Global Burden of Disease (GBD)
project estimated there were more than 1.2 million deaths in 2016
due to cirrhosis and chronic liver disease, of which more than one
quarter were related to alcoholic liver diseases.3 Patients with
severe ASH may develop the acute clinical entity of alcoholic
hepatitis, a disease characterized by jaundice and liver failure.
Of the patients who survive alcoholic hepatitis, 70% will develop
cirrhosis. By contrast, 40% of patients with alcoholic liver
cirrhosis may also develop alcoholic hepatitis (acute-on-chronic
disease), with very high mortality rates.1
About Innovate Biopharmaceuticals, Inc. (Nasdaq:
INNT)Innovate is a clinical stage biotechnology company
focused on developing novel therapeutics for autoimmune and
inflammatory diseases. Innovate’s lead drug candidate, larazotide
acetate, has a mechanism of action that renormalizes the
dysfunctional intestinal barrier by decreasing intestinal
permeability and reducing antigen trafficking, such as gliadin
fragments in celiac disease, and bacterial toxins and immunogenic
antigens in nonalcoholic steatohepatitis (NASH). In several
diseases, including celiac disease, NASH, Crohn’s disease,
ulcerative colitis, irritable bowel syndrome (IBS), type 1 diabetes
mellitus (T1DM), chronic kidney disease (CKD), the intestinal
barrier is dysfunctional with increased permeability.
Forward Looking StatementsThis press release
includes forward-looking statements including, but not limited to,
statements related to the development of drug candidates, our
operations and business strategy, capital raising, our expected
financial results, and corporate updates. The forward-looking
statements contained in this press release are based on
management’s current expectations and are subject to substantial
risks, uncertainty and changes in circumstances. Actual results may
differ materially from those expressed by these expectations due to
risks and uncertainties, including, among others, those related to
our ability to obtain additional capital on favorable terms to us,
or at all, including, without limitation, to fund our current and
future preclinical studies and clinical trials, including, without
limitation, raising additional funds for our Phase 3 registration
trial for INN-202, and the success, timing and cost of our drug
development program and our ongoing or future preclinical studies
and clinical trials, including, without limitation, the possibility
of unfavorable new clinical and preclinical data and additional
analyses of existing data, as well as the risks that prior clinical
and preclinical results may not be replicated. These risks and
uncertainties include, but may not be limited to, those described
in our Annual Report on Form 10-K filed with
the SEC on March 18, 2019, and in any subsequent
filings with the SEC. Forward-looking statements speak only as
of the date of this press release, and we undertake no obligation
to review or update any forward-looking statement except as may be
required by applicable law.
SOURCE: Innovate Biopharmaceuticals, Inc.
Contact:Jennifer K. Zimmons, Ph.D.Investor
RelationsTel: +1-917-214-3514Email:
jzimmons@innovatebiopharma.comwww.innovatebiopharma.com
References:1. Seitz H.K., Mueller S. (2010)
Alcoholic Liver Disease. In: Clinical Hepatology. Springer, Berlin,
Heidelberg (DOI: https://doi.org/10.1007/978-3-642-04519-6_34)
Innovate Biopharmaceutic... (NASDAQ:INNT)
Historical Stock Chart
From Jul 2024 to Aug 2024
Innovate Biopharmaceutic... (NASDAQ:INNT)
Historical Stock Chart
From Aug 2023 to Aug 2024